title: D-psicose, a sweet monosaccharide, ameliorate hyperglycemia, and dyslipidemia in C57BL/6J db/db mice.
abstract: D-psicose has been implicated in glycemic control in recent animal and human studies. In this study, the effects of D-psicose on glycemic responses, insulin release, and lipid profiles were compared with those of D-glucose and D-fructose in a genetic diabetes model. C57BL/6J db/db mice were orally supplemented with 200 mg/kg BW of D-psicose, D-glucose, or D-fructose, respectively, while diabetes control or wild type mice were supplemented with water instead. D-psicose sustained weight gain by about 10% compared to other groups. The initial blood glucose level maintained from 276 to 305 mg/dL during 28 d in the D-psicose group, whereas a 2-fold increase was found in other groups (P < 0.05) among diabetic mice. D-psicose significantly improved glucose tolerance and the areas under the curve (AUC) for glucose among diabetes (P < 0.05), but had no effect on serum insulin concentration. The plasma lipid profile was not changed by supplemental monosacchrides, although the ratio of LDL-cholesterol/HDL-cholesterol was ameliorated by D-psicose. The administration of D-psicose reversed hepatic concentrations of triglyceride (TG) and total cholesterol (TC) by 37.88% and 62.89%, respectively, compared to the diabetes control (P < 0.05). The current findings suggest that D-psicose shows promise as an antidiabetic and may have antidyslipidemic effects in type 2 diabetes.
authors.affiliation: Dept. of Food and Nutrition, Hanyang Univ., Seoul 133-791, Korea.
authors.forename: S H
authors.initials: SH
authors.lastname: Baek
authors.forename: S J
authors.initials: SJ
authors.lastname: Park
authors.forename: H G
authors.initials: HG
authors.lastname: Lee
mesh_terms: D000818:Animals; D019540:Area Under Curve; D001786:Blood Glucose / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism*; D019587:Dietary Supplements; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000097:blood* / Q000517:prevention & control; D005243:Feces; D005632:Fructose / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D005947:Glucose / Q000008:administration & dosage; D006943:Hyperglycemia / Q000097:blood* / Q000517:prevention & control; D007328:Insulin / Q000097:blood; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D014867:Water / Q000008:administration & dosage; D015430:Weight Gain / Q000187:drug effects
chemical_list: D001786:Blood Glucose; D007328:Insulin; D014867:Water; C003243:psicose; D005632:Fructose; D005947:Glucose